Global health tech firm CardieX Subsidiary ATCOR collaborates with Power to Advance Patient Recruitment Diversity By CIOTechOutlook Team

Global health tech firm CardieX Subsidiary ATCOR collaborates with Power to Advance Patient Recruitment Diversity

CIOTechOutlook Team | Tuesday, 07 February 2023, 11:32 IST

  •  No Image
A partnership between its ATCOR subsidiary and Power, a rapidly expanding patient recruitment marketplace that democratises access to clinical trials for all patients, has been announced by CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes.
 
The new collaboration will enable ATCOR and Power to carry out joint research and improve the accessibility to clinical trials and clinical research for underserved patients in the fields of Alzheimer's disease, women's health, diabetes, and cardiovascular disease.
 
The partnership's main objective is to introduce innovative methods for patient screening using fresh inclusion/exclusion criteria for all clinical trial models (traditional, hybrid, and decentralised), in order to broaden both patient access and patient diversity. Using digital vascular biomarkers in conjunction with ATCOR's SphygmoCor® technology and Power's patient-searchable platform will allow for a cutting-edge strategy to benchmark the future of patient recruitment and improve patient-reported results.
 
Starting with patient awareness of available clinical trials through Power's user-friendly patient platform, patients can gain personalised access to medicines. ATCOR's crucial digital vascular biomarkers for patient-centric screening are included in the improved protocol design, which results in a contemporary, holistic paradigm for inclusion/exclusion criteria across populations. To increase trust in the clinical trial process among various communities, the existing patient recruitment method must be changed. This requires both patient empowerment and patient-centric screening.
 
The "Pulse", a new medical device from CardieX subsidiary CONNEQT, will provide advanced arterial health metrics to users from the comfort of their own home. Pulse was developed as a primary decentralized clinical trial device enhancing patient-centric screening and monitoring. The Pulse enables any patient anywhere to be part of clinical trials.  Through the use of digital vascular biomarkers in the protocol, the Pulse enables customized patient recruitment to enhance diversity across populations.
 
In order to enable patients to find therapeutic specialties that have personal significance for them, Power has developed an equal access and user-friendly recruitment platform. Making clinical trials available and taking into account the socioeconomic, regional, and ethnic diversity of today gives patients a choice and invites them to take part in the development of medical research.
 
"I am excited to partner with Power to advance patient recruitment diversity.  Our ATCOR and Power partnership brings forward tremendous opportunity to push the boundaries of diversity within clinical trials.  We will open doors for patients 'anywhere' to have equal access to clinical research and use our digital vascular biomarkers to enhance inclusion/exclusion criteria." said Toni R. Hofhine, President of CardieX subsidiary ATCOR Medical.
 
"Advancing underrepresented populations is essential for improving patient reported outcomes.  The ATCOR and Power partnership will expand patient diversity across all clinical trial models, and I am excited to see the combined technologies engage the patient across some of the most challenging areas in medical research." said Craig Cooper, Group CEO of the CardieX companies.
 
"Increasing patient access is key to improving representation in clinical research.  Unfortunately, we don't adequately understand the structural barriers that are often unintentionally exclusionary to people of colour.  I am excited to see our partnership with ATCOR begin to break down some of these barriers."  Said Brandon Li, Power cofounder.
 
In the upcoming months, the Pulse device will be accessible for clinical trials and medical research.

CIO Viewpoint

Product Adoption: Realizing The Real Value

By Ashish Pandey, CIO, GSK Consumer Healthcare India

CXO Insights

HIT Promotional Products: Fostering Empowerment...

By Eric Shonebarger, President & Lori Thibado, Director of Order Entry & Art

Elevating Patient Experience with Remote...

By Vineet Aggarwal, CIO, Paras Healthcare

Facebook